WO2008033351A3 - Multimodal abuse resistant and extended release formulations - Google Patents
Multimodal abuse resistant and extended release formulations Download PDFInfo
- Publication number
- WO2008033351A3 WO2008033351A3 PCT/US2007/019745 US2007019745W WO2008033351A3 WO 2008033351 A3 WO2008033351 A3 WO 2008033351A3 US 2007019745 W US2007019745 W US 2007019745W WO 2008033351 A3 WO2008033351 A3 WO 2008033351A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extended release
- multimodal
- abuse resistant
- release formulations
- abuse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is in the field of oral, abuse resistant pharmaceutical compositions of abusable drugs, extended release pharmaceutical compositions of abusable drugs and extended release abuse resistant pharmaceutical compositions of abusable drugs and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84339206P | 2006-09-11 | 2006-09-11 | |
US60/843,392 | 2006-09-11 | ||
US90798707P | 2007-04-26 | 2007-04-26 | |
US60/907,987 | 2007-04-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008033351A2 WO2008033351A2 (en) | 2008-03-20 |
WO2008033351A3 true WO2008033351A3 (en) | 2009-04-09 |
Family
ID=39184298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/019745 WO2008033351A2 (en) | 2006-09-11 | 2007-09-12 | Multimodal abuse resistant and extended release formulations |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008033351A2 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
US8329744B2 (en) | 2005-11-02 | 2012-12-11 | Relmada Therapeutics, Inc. | Methods of preventing the serotonin syndrome and compositions for use thereof |
ES2400446T5 (en) | 2006-08-03 | 2017-03-13 | Horizon Pharma Ag | Treatment with delayed-release glucocorticoids of a rheumatic disease |
WO2009112874A1 (en) * | 2008-03-10 | 2009-09-17 | Eurodrug Laboratories B.V. | Modified release composition comprising doxofylline |
EP2457561A4 (en) * | 2009-07-06 | 2014-03-05 | Kyorin Seiyaku Kk | Tablet having hollow structure |
AT509000B1 (en) * | 2009-10-23 | 2012-12-15 | Rausch Peter | WATER-SOLUBLE PREPARATIONS OF CANNABINOIDS AND CANNABIC PREPARATIONS AND THEIR APPLICATIONS |
US9125867B2 (en) | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
FR2962331B1 (en) * | 2010-07-06 | 2020-04-24 | Ethypharm | PHARMACEUTICAL FORM FOR COMBATING CHEMICAL SUBMISSION, METHOD USING THE SAME |
FR2962550B1 (en) * | 2010-07-06 | 2013-06-14 | Ethypharm Sa | METHOD FOR CONTROLLING CHEMICAL SUBMISSION, USE OF COLORING AGENT FOR COMBATING CHEMICAL SUBMISSION AND PHARMACEUTICAL COMPOSITION FOR THE IMPLEMENTATION OF THE METHOD |
CN111557432B (en) | 2013-02-08 | 2023-08-04 | 通用磨坊公司 | Low sodium food |
CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
JP2022522270A (en) | 2019-03-01 | 2022-04-15 | フラメル アイルランド リミテッド | Gamma-hydroxybutyrate composition with improved pharmacokinetics in dietary intake |
WO2021151168A1 (en) * | 2020-01-31 | 2021-08-05 | AusCann Group Holdings Ltd | Method of cannabinoid therapy |
WO2021151169A1 (en) * | 2020-01-31 | 2021-08-05 | AusCann Group Holdings Ltd | Cannabinoid composition and manufacturing method |
CN116261451A (en) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | Pharmaceutical compositions and pharmacokinetics of gamma-hydroxybutyric acid derivatives |
CA3194665A1 (en) | 2020-10-05 | 2022-04-14 | Jia-Ning Xiang | Modified release compositions of a gamma-hydroxybutyric acid derivative |
CN117098533A (en) | 2021-03-19 | 2023-11-21 | 凯瑞康宁公司 | Pharmacokinetics of a combination release formulation of gamma-hydroxybutyric acid derivatives |
EP4346788A2 (en) | 2021-06-03 | 2024-04-10 | Arcadia Medicine, Inc. | Enantiomeric entactogen compositions and methods of their use |
WO2023034510A1 (en) | 2021-09-01 | 2023-03-09 | ATAI Life Sciences AG | Synthesis of mdma or its optically active ( r)- or ( s)-mdma isomers |
US11845736B2 (en) | 2021-10-01 | 2023-12-19 | Empathbio, Inc. | Prodrugs of MDMA, MDA, and derivatives thereof |
US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228863B1 (en) * | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
US6309668B1 (en) * | 1994-02-01 | 2001-10-30 | Aventis Pharma Limited | Abuse resistant tablets |
-
2007
- 2007-09-12 WO PCT/US2007/019745 patent/WO2008033351A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309668B1 (en) * | 1994-02-01 | 2001-10-30 | Aventis Pharma Limited | Abuse resistant tablets |
US6228863B1 (en) * | 1997-12-22 | 2001-05-08 | Euro-Celtique S.A. | Method of preventing abuse of opioid dosage forms |
Also Published As
Publication number | Publication date |
---|---|
WO2008033351A2 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008033351A3 (en) | Multimodal abuse resistant and extended release formulations | |
WO2007087452A3 (en) | Abuse resistant and extended release formulations and method of use thereof | |
WO2008027442A3 (en) | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use | |
AU2003280087A1 (en) | Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton | |
WO2007146248A3 (en) | Stable laquinimod preparations | |
WO2008021394A3 (en) | Pharmaceutical formulations of cannabinoids and method of use | |
WO2008024490A3 (en) | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use | |
IL228017A0 (en) | Substituted quinazolinone derivative, pharmaceutical composition comprising same and use thereof for preparation of a medicament | |
ZA200901110B (en) | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage from containing same | |
WO2006096439A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
IL193240A0 (en) | Dihydrodiazepine derivatives and pharmaceutical compositions containing the same | |
IL196169A0 (en) | Bile acid derivatives and pharmaceutical compositions containing the same | |
WO2007087431A3 (en) | Sublingual fentanyl spray | |
WO2008024408A3 (en) | Pharmaceutical formulations of cannabinoids for application to the skin and method of use | |
WO2008066899A3 (en) | Nanoparticulate formulations and methods for the making and use thereof | |
EP1824442A4 (en) | Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant | |
IL194954A0 (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
WO2008049116A3 (en) | Substituted indoles | |
IL193772A0 (en) | 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same | |
AP2008004671A0 (en) | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof | |
EP1993519A4 (en) | Methods and compositions for deterring abuse of orally administered pharmaceutical products | |
WO2009081174A3 (en) | Anti - retroviral combination | |
WO2005117895A8 (en) | Compositions comprising meloxicam | |
WO2008006795A3 (en) | Indole compounds | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07838038 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07838038 Country of ref document: EP Kind code of ref document: A2 |